Molekulare und genetische Medizin

Cancer Genomics in the Era of Checkpoint Inhibition: Biomarkers to Predict Tumor Response to Checkpoint Inhibition Therapy

Abstract

Kim S

With their ground-breaking clinical success, immune checkpoint inhibitors (ICIs) have opened a new chapter in cancer treatment; however, not all patients have a response to ICI treatment. Current approaches to maximizing the efficacy of ICI treatment include combining it with conventional cancer treatments and identifying biomarkers that accurately predict tumor responses to ICI agents. This mini-review introduces genomic determinants of ICI efficacy and directions for future immunogenomic studies in the era of checkpoint inhibition.